Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Geusens

Showing results (31-40 of 147) with videos related to

Pageof 15
Sort By:
Immunology Letters|September 13, 2005
Impaired activation-induced telomerase activity in PBMC of early but not chronic rheumatoid arthritis patientsMarielle Thewissen, Loes Linsen, Piet Geusens, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 19, 2005
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMDNelson B Watts, Piet Geusens, Ian P Barton, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|April 6, 2024
Follow-up in Fracture Liaisons Services: the involvement of general practitioners and fracture nurses is urgently neededWillem F Lems, Joop P van den Bergh, Piet Geusens
Expert Opinion on Biological Therapy|November 28, 2022
Romosozumab for the treatment of postmenopausal women at high risk of fracturePiet Geusens, Natasha Appelman-Dijkstra, Willem Lems, et al.
Expert Opinion on Drug Discovery|November 24, 2025
The preclinical discovery and development of romosozumab for the treatment of people with severe osteoporosis who are at high risk of fracturePiet Geusens, Wim Van Hul, Joop van den Bergh, et al.
The Journal of Rheumatology|August 4, 2004
Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controlsAnn Vanderborght, Loes Linsen, Mariëlle Thewissen, et al.
Annals of the New York Academy of Sciences|August 30, 2005
Premature immunosenescence in rheumatoid arthritis and multiple sclerosis patientsMarielle Thewissen, Loes Linsen, Veerle Somers, et al.
Archives of Physical Medicine and Rehabilitation|July 5, 2002
The relationship among history of falls, osteoporosis, and fractures in postmenopausal womenPiet Geusens, Philip Autier, Steven Boonen, et al.
The Journal of Rheumatology|October 7, 2004
Clinical vertebral fractures in patients with ankylosing spondylitisDebby Vosse, Ernst Feldtkeller, Jon Erlendsson, et al.
Lancet (London, England)|May 22, 2018
Teriparatide vs risedronate for osteoporosis - Authors' replyDavid L Kendler, Piet Geusens, Cristiano A F Zerbini, et al.
Pageof 15

Showing results (31-40 of 147) with videos related to

Sort By:
Pageof 15
Immunology Letters|September 13, 2005
Impaired activation-induced telomerase activity in PBMC of early but not chronic rheumatoid arthritis patientsMarielle Thewissen, Loes Linsen, Piet Geusens, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 19, 2005
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMDNelson B Watts, Piet Geusens, Ian P Barton, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|April 6, 2024
Follow-up in Fracture Liaisons Services: the involvement of general practitioners and fracture nurses is urgently neededWillem F Lems, Joop P van den Bergh, Piet Geusens
Expert Opinion on Biological Therapy|November 28, 2022
Romosozumab for the treatment of postmenopausal women at high risk of fracturePiet Geusens, Natasha Appelman-Dijkstra, Willem Lems, et al.
Expert Opinion on Drug Discovery|November 24, 2025
The preclinical discovery and development of romosozumab for the treatment of people with severe osteoporosis who are at high risk of fracturePiet Geusens, Wim Van Hul, Joop van den Bergh, et al.
The Journal of Rheumatology|August 4, 2004
Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controlsAnn Vanderborght, Loes Linsen, Mariëlle Thewissen, et al.
Annals of the New York Academy of Sciences|August 30, 2005
Premature immunosenescence in rheumatoid arthritis and multiple sclerosis patientsMarielle Thewissen, Loes Linsen, Veerle Somers, et al.
Archives of Physical Medicine and Rehabilitation|July 5, 2002
The relationship among history of falls, osteoporosis, and fractures in postmenopausal womenPiet Geusens, Philip Autier, Steven Boonen, et al.
The Journal of Rheumatology|October 7, 2004
Clinical vertebral fractures in patients with ankylosing spondylitisDebby Vosse, Ernst Feldtkeller, Jon Erlendsson, et al.
Lancet (London, England)|May 22, 2018
Teriparatide vs risedronate for osteoporosis - Authors' replyDavid L Kendler, Piet Geusens, Cristiano A F Zerbini, et al.
Pageof 15